{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:28:29Z","timestamp":1790677709356,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Psychopharmacol"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose\/Background<\/jats:title>\n            <jats:p>Activating and sedating adverse effects of antipsychotics can be obstacles to their use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/Procedures<\/jats:title>\n            <jats:p>This study quantified the activating and sedating properties of first-line oral second-generation antipsychotics by examining the rates of adverse reactions as reported in product labeling for the indications of schizophrenia and adjunctive treatment of major depressive disorder. Additional data sources included regulatory documents, study synopses, and published study reports. Attributable risk increase and number needed to harm (NNH) were calculated for each agent versus placebo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Findings\/Results<\/jats:title>\n            <jats:p>Heterogeneity among the different antipsychotics regarding activating or sedating adverse events was observed, with some agents displaying the potential for both activating and sedating properties. For agents indicated for the treatment of schizophrenia, predominantly activating medications include lurasidone (NNH, 11 for akathisia vs 20 for somnolence) and cariprazine (NNH, 15 for akathisia vs 65 for somnolence-combined terms). Similarly activating and sedating are risperidone (NNH, 15 for akathisia vs 13 for sedation) and aripiprazole (NNH, 31 for akathisia vs 34 for somnolence). Predominantly sedating are olanzapine, quetiapine immediate and extended release, ziprasidone, asenapine, and iloperidone. Agents that are neither activating nor sedating are paliperidone and brexpiprazole. For major depressive disorder, the overall findings regarding activation and sedation appear similar to those seen with schizophrenia. Data extracted were limited to those available from registrational studies that contributed to the adverse event tables contained in the product labels. Postregistrational comparative studies may yield different outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Implications\/Conclusions<\/jats:title>\n            <jats:p>Differences in tolerability profiles regarding activation and sedation have implications in terms of selecting the optimal antipsychotic for a given individual.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/jcp.0000000000000665","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T11:56:07Z","timestamp":1486727767000},"page":"138-147","source":"Crossref","is-referenced-by-count":80,"title":["Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder"],"prefix":"10.1097","volume":"37","author":[{"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20231030","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-244X-13-50","article-title":"The nature of relapse in schizophrenia","volume":"13","year":"2013","journal-title":"BMC Psychiatry"},{"key":"bib2-20231030","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","year":"2010","journal-title":"Am Fam Physician"},{"key":"bib3-20231030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ajp.2014.08.002","article-title":"Antipsychotic treatment of schizophrenia: an update","volume":"11","year":"2014","journal-title":"Asian J Psychiatr"},{"key":"bib4-20231030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3810\/pgm.2010.07.2174","article-title":"Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"122","year":"2010","journal-title":"Postgrad Med"},{"key":"bib5-20231030","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","year":"2013","journal-title":"Lancet"},{"key":"bib6-20231030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-244X-12-20","article-title":"A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia","volume":"12","year":"2012","journal-title":"BMC Psychiatry"},{"key":"bib7-20231030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488609789006985","article-title":"Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications","volume":"4","year":"2009","journal-title":"Curr Drug Saf"},{"key":"bib8-20231030","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","article-title":"Compelling or irrelevant? Using number needed to treat can help decide","volume":"117","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"bib9-20231030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0447.2009.01449.x","article-title":"Relative vs. absolute measures of benefit and risk: what\u2019s the difference?","volume":"121","year":"2010","journal-title":"Acta Psychiatr Scand"},{"key":"bib10-20231030","first-page":"42","article-title":"Beyond PubMed: searching the \u201cgrey literature\u201d for clinical trial results","volume":"11","year":"2014","journal-title":"Innov Clin Neurosci"},{"key":"bib55-20231030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/YIC.0000000000000110","article-title":"Cariprazine in the treatment of schizophrenia: a proof-of-concept trial","volume":"31","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"key":"bib56-20231030","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","year":"2014","journal-title":"Schizophr Res"},{"key":"bib57-20231030","doi-asserted-by":"crossref","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial","volume":"76","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"bib58-20231030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial","volume":"35","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"bib59-20231030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4088\/JCP.08m04064","article-title":"An integrated analysis of olanzapine\/fluoxetine combination in clinical trials of treatment-resistant depression","volume":"70","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"bib60-20231030","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","article-title":"Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study","volume":"70","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"bib61-20231030","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S1461145710000015","article-title":"Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study","volume":"13","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"bib62-20231030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jad.2010.08.032","article-title":"A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder","volume":"127","year":"2010","journal-title":"J Affect Disord"},{"key":"bib63-20231030","first-page":"3095","article-title":"Lack of tolerable treatment options for patients with schizophrenia","volume":"11","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"bib64-20231030","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40263-013-0105-7","article-title":"A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach","volume":"27","year":"2013","journal-title":"CNS Drugs"},{"key":"bib65-20231030","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/14737175.2013.811984","article-title":"New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia","volume":"13","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"bib66-20231030","doi-asserted-by":"crossref","first-page":"e1002127","DOI":"10.1371\/journal.pmed.1002127","article-title":"Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review","volume":"13","year":"2016","journal-title":"PLoS Med"},{"key":"bib67-20231030","first-page":"i5078","article-title":"Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry\/journal editor perspective","volume":"355","year":"2016","journal-title":"BMJ"},{"key":"bib68-20231030","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/ijcp.12899","article-title":"The grey literature is far from drab","volume":"70","year":"2016","journal-title":"Int J Clin Pract"},{"key":"bib69-20231030","first-page":"64981","article-title":"Clinical trials registration and results information submission. Final rule","volume":"81","year":"2016","journal-title":"Fed Regist"},{"key":"bib70-20231030","first-page":"64922","article-title":"NIH policy on the dissemination of NIH-funded clinical trial information","volume":"81","year":"2016","journal-title":"Fed Regist"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00004714-201704000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T20:36:38Z","timestamp":1698698198000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201704000-00006"}},"subtitle":["Absolute Risk Increase and Number Needed to Harm"],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0000000000000665","relation":{},"ISSN":["1533-712X","0271-0749"],"issn-type":[{"value":"1533-712X","type":"electronic"},{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}